Powell Gilbert LLP

Penny Gilbert

Current View:
Also ranked in:

This content is provided by Penny Gilbert.

Practice Areas

Penny specialises in litigation and advisory work relating to intellectual property rights particularly in the pharmaceutical and biotechnology fields. Her background in the life sciences has lead to her acting in patent litigation for clients ranging from pharmaceutical multinationals to early stage biotech companies including, for example, HGS, GSK, Biogen, Napp, Pharmaq and Kymab. She has also acted in litigation and arbitrations over disputed technology contracts, including patent licences. She is experienced in co-ordinating multi-jurisdictional litigation, has represented clients in European Patent Office opposition proceedings and in referrals to the CJEU and EFTA Court on the SPC Regulation. She also advises on freedom-to-operate issues. Penny is also a qualified mediator and a solicitor advocate.

Career

Brasenose College, Oxford (1982 MA Biochemistry, 1986 DPhil Molecular Biology); Bristol University (Diploma in IP Law); Qualified Bristows 1991; Partner, Bristows 1998-2007; Partner, Powell Gilbert LLP 2007.

Professional Memberships

Past president and advisory board member of EPLAW; Member of AIPPI; LSLA; IPLA; LES.

Work Highlights

Forty Seven v SSB (therapeutic antibodies); Eli Lilly v Eisai (Alzheimer therapies);

Mylan v Sandoz (protein purification); Samsung Bioepis & Biogen v AbbVie (adalimumab);

GlaxoSmithKline Biologicals v UCB Pharma (vaccines); Icahn School of Medicine at Mount Sinai (SPCs – agalsidase beta); Regeneron v Kymab (antibodies / transgenic mice);

Pharmaq v Intervet (SPCs – veterinary vaccine); Eli Lilly v Biogen (monoclonal antibody use); Synageva v CHRF/Shire (orphan drug / enzyme replacement therapy); Eli Lilly v Human Genome Sciences (neutrokine alpha); Eli Lilly v Human Genome Sciences (SPCs – neutrokine alpha); Hospira v Amgen (protein pegylation); Sandoz / ratiopharm v Napp (controlled release oxycodone formulations); Roche v Chiron (SPCs – trastuzumab and enfuvirtide); Oxford Gene Technology v Affymetrix (DNA microarrays); Pharmacia v Merck (COX 2 inhibitors); Inhale v Quadrant (protein stabilisation); Quadrant v Roser (protein stabilisation); Chiron v Murex & Others (HCV); Chiron v Evans Medical & Others (pertussis antigens); Genentech v Wellcome (tPA); Genentech v Eli Lilly (HGH)

Industry Sector Expertise

Life Sciences/Pharmaceuticals and biotechnology

Chemicals

Medical devices

Awards

IP Star and Top 250 Women in IP

Managing Intellectual Property

2019

Influential Women in IP

WIPR

2019

Global Elite Thought Leader

Who's Who Legal Patents and Life Sciences

2019

Expert Guides - Patents UK, Best of the Best

2018

Top 50 Life Sciences Leaders

LSIPR

2018